Local News

• AstraZeneca granted temporary restraining order in PULMICORT RESPULES patent litigation  On 19 November 2008, AstraZeneca was granted a Temporary Restraining Order (TRO) by the United States District Court for the District of New Jersey, halting sales of Teva's budesonide inhalation suspension product, a generic version of AstraZeneca's PULMICORT RESPULES treatment.
  AstraZeneca November 20, 2008  
• AstraZeneca to realign supply chain to improve productivity and move closer to customers  AstraZeneca has announced proposed changes to its global manufacturing and supply chain operations as part of its ongoing programme to improve efficiency across the business.
  AstraZeneca November 20, 2008  
• FDA Advisory Committee provides opinion on oritavancin  Targanta Therapeutics announced that oritavancin, the Company's investigational antibiotic therapy for the treatment of complicated skin and skin structure infections (cSSSI) caused by gram-positive pathogens, received a mixed review from the FDA's Anti-Infective Drugs Advisory Committee.
  Targanta Therapeutics Corporation November 19, 2008  
• Amgen, Takeda and Millennium provide update on Phase 3 trial of motesanib  Amgen and Millennium announced that enrollment in the Phase 3 MONET1 trial evaluating motesanib (AMG 706) in combination with paclitaxel and carboplatin for the first-line treatment of advanced non-small cell lung cancer (NSCLC) has been temporarily suspended.
  Amgen November 19, 2008  
• Charles River promotes Foster Jordan to Corporate Senior Vice President  Charles River Laboratories International announced the promotion of Foster Jordan to Corporate Senior Vice President, Endotoxin & Microbial Detection Products.
  Charles River Laboratory International November 19, 2008  
• Covidien launches improved Magellan Safety Hypodermic Needle  Covidien announced that it is launching a new and improved Magellan(TM) Safety Hypodermic Needle. The development of the new design, which gives clinicians more control and smoother activation of the safety shield, reflects Covidien's continued commitment to improving healthcare worker safety.
  Covidien November 19, 2008  
• AstraZeneca enters agreement for authorized generic Pulmicort Respules  AstraZeneca announced that it has entered into a supply and distribution agreement with Par Pharmaceutical to distribute an authorized generic version of budesonide inhalation suspension in the United States in response to the launch 'at risk' of a generic version of this product by Teva.
  AstraZeneca November 19, 2008  
• FDA opens 1st office in China  U.S. officials are launching a new strategy to improve the safety of the vast range of foods and other products imported from China and other countries to the United States. The Food and Drug Administration is opening its first office outside the United States in Beijing.
  Austin American-Statesman (Texas) November 19, 2008  Craig Simons
• Bruker announces order for 10 NMR systems from KAUST  Bruker BioSpin announces that it has received an order from King Abdullah University of Science and Technology (KAUST) for ten (10) Nuclear Magnetic Resonance (NMR) spectrometers valued at close to $20 million, including Bruker's flagship 950 MHz superconducting NMR magnet.
  Bruker Corporation November 19, 2008  
• FDA responds to AstraZeneca’s citizen petition  On 18 November 2008, the US FDA responded to AstraZeneca's Citizen Petition surrounding the company's concern about the approval of any generic version of PULMICORT RESPULES(R) (budesonide inhalation suspension).
  AstraZeneca November 19, 2008  

   (next 10 articles)